5-Alpha Reductase Deficiency Market Report 2026

The 5-alpha reductase deficiency market size has grown strongly in recent years. It will grow from $1.5 billion in 2025 to $1.64 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to limited awareness of rare genetic disorders, reliance on clinical evaluation for diagnosis, gradual adoption of hormone testing, increasing hospital-based treatment, slow development of specialized surgical procedures.

The 5-alpha reductase deficiency market size is expected to see strong growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to advancements in gene sequencing technologies, rising newborn and carrier screening programs, increasing focus on personalized hormone therapy, growth in specialty clinics for rare disorders, expanding research in genetic endocrinology. Major trends in the forecast period include increasing early diagnosis of 5-alpha reductase deficiency, rising awareness of disorders of sexual development, growing adoption of genetic and hormonal testing, expansion of specialized endocrinology and urology care, improved access to hormone replacement therapies.

The increasing number of research and development activities in genomics is playing a significant role in driving the growth of the 5-alpha reductase deficiency market. Genomics involves the study of an individual’s entire gene pool (genome), including how genes interact with each other and with the environment. Genomics is applied to diagnose 5-alpha reductase deficiency by detecting specific genetic mutations responsible for the disorder. Consequently, research and development efforts in genomics contribute to the discovery and treatment of the condition. For instance, in February 2025, data from the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, indicated that U.S. research and development expenditures increased from $892 billion in 2022 to $940 billion in 2023, reflecting a $48 billion rise. Therefore, the growing number of research and development activities in genomics is expected to drive the 5-alpha reductase deficiency market.

Major companies operating in the 5-alpha reductase deficiency market are concentrating on developing technologically advanced products, such as consumer-initiated genetic tests, which allow individuals to access personal genetic information directly and privately without needing a referral from a healthcare provider. A consumer-initiated genetic test is a form of genetic testing that individuals order directly from a laboratory or testing company, usually without the involvement of a healthcare professional, to gain insights into their genetic predispositions, ancestry, or health-related traits. For instance, in July 2023, Quest Diagnostics, a US-based provider of diagnostic information services, introduced Genetic Insights, a consumer-initiated genetic test. This offering helps individuals evaluate their potential risk of developing certain hereditary health conditions. It features advanced technology and comprehensive support, including personalized health reports and access to genetic counseling. By analyzing a saliva sample, Genetic Insights assesses 36 genes to determine the risk of nearly two dozen hereditary conditions, such as breast and colon cancer, various cardiovascular and blood disorders, as well as carrier status for cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. The test is designed to address gaps in existing consumer genetic tests and employs cutting-edge next-generation sequencing (NGS) technology, which can analyze thousands of DNA variants in disease-related genes and examine more regions of the genome compared to traditional microarray testing.

In April 2023, Blue Water Vaccines Inc., a US-based biopharmaceutical company, acquired ENTADFI (finasteride/tadalafil) from Veru Inc. for approximately $100 million. Through this acquisition, Blue Water expanded its scope to include multiple pharmaceutical sectors. The acquisition enables the company to enter the commercial market while offsetting operational costs and providing essential revenue to support its vaccine candidate pipeline. Blue Water’s primary mission of assisting patients in need remains strong, with plans to further develop this asset and expand its pipeline for patients worldwide. Veru Inc., a US-based biopharmaceutical company, offers ENTADFI (finasteride/tadalafil), which targets the 5-alpha-reductase enzyme.

Major companies operating in the 5-alpha reductase deficiency market are F. Hoffmann-La Roche Ltd, Sanofi SA, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Johnson and Johnson Services Inc, Novo Nordisk A S, Regeneron Pharmaceuticals Inc, Roivant Sciences Ltd, Sanofi Genzyme, Shionogi and Co Ltd, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, UCB S A, Vertex Pharmaceuticals Incorporated, Cadila Healthcare Limited, Endo International plc.

North America was the largest region in the 5-alpha reductase deficiency market in 2025. The regions covered in the 5-alpha reductase deficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the 5-alpha reductase deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the 5-alpha reductase deficiency market by increasing costs for imported diagnostic equipment, genetic testing kits, and hormone therapy products. Diagnostic segments such as gene sequencing and imaging tests are most affected, particularly in regions dependent on imports like asia-pacific and parts of latin america. Higher tariffs have led to increased treatment and testing costs for healthcare providers. However, they have also encouraged local manufacturing of diagnostic kits and improved regional self-reliance in rare disease testing solutions.

The 5-alpha reductase deficiency market research report is one of a series of new reports that provides 5-alpha reductase deficiency market statistics, including 5-alpha reductase deficiency industry global market size, regional shares, competitors with a 5-alpha reductase deficiency market share, detailed 5-alpha reductase deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the 5-alpha reductase deficiency industry. This 5-alpha reductase deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

5-alpha reductase deficiency is a condition that impacts male sexual development both before and during puberty. Individuals with this disorder do not produce sufficient levels of dihydrotestosterone, a hormone essential for male sexual development.

The primary methods for diagnosing 5-alpha reductase deficiency include chromosome analysis, gene sequencing, hormone tests, imaging tests, genetic screening, and others. Chromosome analysis is used to determine whether a patient has XX (female) or XY (male) chromosomes. Treatment options include surgery, vaginoplasty, feminizing genitoplasty, hormone replacement therapy, and others. The end users of these treatments include hospitals, specialty clinics, and other healthcare providers.

The 5-alpha reductase deficiency market includes revenues earned by entities by providing ultrasound screening diagnosis and surgical procedures to treat 5-alpha reductase deficiencies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.